Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on DMARDs

Posted by Matt Breese on Oct 15, 2015

Find me on:

With a network across healthcare in pharma, payer and provider, MMIT's team of experts takes a closer look at Disease Modifying Agents in our most recent Reality Check. The following highlights some of our key takeaways from the piece, which can be viewed below.

Payer Coverage: Utilization management policies from the top 10 payers reveal the dominance of step therapies in this market basket. Most plans require the majority of the class to step through preferred products with roughly 40% requiring 2 steps.

Source: MMIT data as of Q4 2015

Trends: Recent DMARDs news reveals some key trends within the market basket. The opportunity for biosimilars in this class is marked as the beginning of a new era by The Motely Fool. On the heels of the Affordable Care Act, Novartis targets Amgen's Enbrel with its 2nd biosimilar application. Medscape also calls out the drug development within Disease Modifying Agents. Several key pharma players are infusing massive R&D into JAK inhibitors and oral biologics.

Key Findings: MMIT's pharmacists reveal several key findings when taking a closer look at the data for Disease Modifying Agents. As JAK inhibitors, several anti-interleukins and the newer PDE4 inhibitors enter the market, the definition of this market basket is quickly evolving. The influx of biologics and biosimilars could crowd an already crowded market, depending on indications. Finally, products launching into this market are tasked with developing strategies that consider the two strongholds in DMARDs, Humira and Enbrel.

In the full Reality Check on Disease Modifying Agents below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access, payer coverage and summarizes key findings within DMARDs.

 View Reality Check

Topics: Market Access